ACT appointed for POLB 001 Phase 2a Trial and supply of approved bispecific antibody drug secured at no cost Trial to take place at The Christie NHS Foundation Trust and other leading UK

Poolbeg Pharma plc (AIM: POLB) has entered 2025 with renewed momentum and a clear strategic focus following an oversubscribed £4.865 million equity raise and a series of high-impact developments across

Director Dealing

Poolbeg Pharma PLC (AIM: POLB) has received a significant regulatory endorsement from US authorities for one of its experimental treatments, which aims to address a serious side effect of advanced

Poolbeg Pharma plc (AIM: POLB), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that, further to the announcements made on 20

Poolbeg Pharma plc (AIM: POLB, ‘Poolbeg Pharma’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that, further to

Poolbeg to present at Master Investor Show, BioTrinity & Participate in a Panel Discussion at LSX World Congress

Grant further strengthens Poolbeg’s global intellectual property (“IP”) portfolio

Termination of proposed combination with HOOKIPA Pharma Inc.